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Serotonin signals through a gut-liver axis to
regulate hepatic steatosis
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Gerard Karsenty 7, Young Seok Ju 1, Chan Choi8, Jae Myoung Suh1,3, Jun Yong Park 4,
Sangkyu Park1,9 & Hail Kim 1,3,10
Nonalcoholic fatty liver disease (NAFLD) is increasing in worldwide prevalence, closely
tracking the obesity epidemic, but speciﬁc pharmaceutical treatments for NAFLD are lacking.
Deﬁning the key molecular pathways underlying the pathogenesis of NAFLD is essential for
developing new drugs. Here we demonstrate that inhibition of gut-derived serotonin synth-
esis ameliorates hepatic steatosis through a reduction in liver serotonin receptor 2A
(HTR2A) signaling. Local serotonin concentrations in the portal blood, which can directly
travel to and affect the liver, are selectively increased by high-fat diet (HFD) feeding in mice.
Both gut-speciﬁc Tph1 knockout mice and liver-speciﬁc Htr2a knockout mice are resistant to
HFD-induced hepatic steatosis, without affecting systemic energy homeostasis. Moreover,
selective HTR2A antagonist treatment prevents HFD-induced hepatic steatosis. Thus, the gut
TPH1-liver HTR2A axis shows promise as a drug target to ameliorate NAFLD with minimal
systemic metabolic effects.
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Nonalcoholic fatty liver disease (NAFLD) refers to a groupof conditions characterized by excessive fat accumulationin the liver. It has become a serious public health problem
globally, affecting more than half a billion people worldwide1, and
is a leading cause of liver transplantation and hepatocellular
carcinoma2,3. However, no pharmacological agents have been
speciﬁcally approved for the treatment of NAFLD4–7. Therefore,
it is necessary to better understand the mechanisms that con-
tribute to the development of NAFLD.
Serotonin (5-hydroxytryptamine (5-HT)) is a monoamine
neurotransmitter that modulates central and peripheral functions.
It is synthesized from the essential amino acid tryptophan and its
production is regulated by the activity of tryptophan hydroxylase
(TPH) and the availability of tryptophan8–10. The two
distinct isoforms of TPH show mutually exclusive tissue expres-
sion patterns: TPH1 in peripheral non-neuronal tissues and
TPH2 in neurons of the central and enteric nervous system11.
Since 5-HT cannot cross the blood brain barrier, central and
peripheral 5-HT systems are functionally separated12. Most of the
peripheral 5-HT is synthesized by TPH1 in enterochromafﬁn cells
of the gut. Once released to the blood circulation, the majority of
5-HT is taken up and sequestered into platelets, whereas the rest
of 5-HT enters the systemic circulation and reaches peripheral
tissues in free form13. Once entering systemic circulation, most of
the free 5-HT is metabolized in liver and lung maintaining free 5-
HT level in peripheral blood at very low levels12,14,15. 5-HT
produced by TPH1 in gut and other peripheral tissues has been
shown to exert speciﬁc biological effects dependent on the context
of target tissues, e.g., adipose tissues, pancreatic β cells, bone, and
liver16–21.
While various functions of peripheral 5-HT are known, the
direct role of 5-HT in regulating hepatic lipid metabolism in vivo
is not well understood. Inhibiting peripheral 5-HT synthesis has
been proposed to prevent NAFLD indirectly by protecting mice
from obesity via thermogenesis in brown adipose tissue (BAT)16.
Increased energy expenditure in BAT is thought to reduce hepatic
lipid inﬂux and thus prevent the development of NAFLD. In
contrast, other studies demonstrated a direct effect of 5-HT on
hepatic lipid accumulation in an in vitro model22. More recently,
we have shown that short-term treatment of TPH inhibitors
prevented the development of hepatic steatosis in mice fed a high
carbohydrate diet without increasing energy expenditure in adi-
pose tissues23. These data prompted us to further explore the
detailed mechanism and function of 5-HT signals regarding liver
energy metabolism in vivo.
Here we show a novel role for gut-derived serotonin (GDS),
through direct actions on liver, in the pathogenesis of hepatic
steatosis.
Results
GDS regulates HFD-induced hepatic steatosis. We ﬁrst exam-
ined the expression of genes involved in 5-HT metabolism in
order to evaluate whether liver could produce 5-HT. Unlike
Slc6a4,Maoa, and Maob, neither Tph1 nor Tph2 was expressed in
the liver, suggesting that the hepatocyte can transport and
metabolize 5-HT but is not likely to produce 5-HT (Fig. 1a). Since
nutrient infusion induces 5-HT production in the gut in human
and the liver is the ﬁrst organ to encounter GDS via the portal
vein, free 5-HT levels in portal blood may reach concentrations
sufﬁcient to have endocrine effects on the liver24. To test this
notion, we measured 5-HT levels in portal blood and peripheral
blood of human subjects. Although the absolute levels of blood 5-
HT varied among individuals, 5-HT concentrations were higher
in portal blood relative to peripheral blood (Fig. 1b and Supple-
mentary Fig. 1a, b). Also, the ratio of 5-HT between portal and
peripheral blood showed a tendency of positive correlation with
markers associated with NAFLD such as blood levels of alanine
transferase (ALT), gamma-glutamyltransferase (GTP), triglycer-
ides (TG), and transient elastography controlled attenuation
parameters (CAP) (Supplementary Fig. 1c)25–27. Next, we asses-
sed changes in 5-HT availability along the gut–liver axis on the
liver in mice presenting with hepatic steatosis after 8 weeks of
high-fat diet (HFD) feeding. Notably, HFD feeding increased
both Tph1 expression and tissue 5-HT level in the gut, and free 5-
HT levels in portal blood (Fig. 1c–e). These data suggest that GDS
production and portal 5-HT concentration can contribute to the
development of NAFLD in both humans and mice.
In order to investigate the functional role of GDS in hepatic
steatosis in vivo, we generated gut-speciﬁc Tph1 knockout (KO)
(Villin-Cre+/–; Tph1ﬂox/ﬂox, herein named Tph1 GKO) mice
(Supplementary Fig. 1d, e) and induced hepatic steatosis with
8 weeks of HFD feeding. Tph1 GKO mice showed no histological
difference in liver compared to wild-type (WT) littermates
(Tph1ﬂox/ﬂox) in standard chow diet (SCD) feeding conditions
(Supplementary Fig. 1f). However, when hepatic steatosis was
induced with 8 weeks of HFD feeding, hepatic lipid droplet
accumulation, NAFLD activity score (NAS), and hepatic TG
levels were dramatically reduced in the liver of HFD-fed Tph1
GKO mice (Fig. 1f–h)28, indicating that reduced GDS production
inhibits the progression of NAFLD.
GDS does not affect systemic energy metabolism. Hepatic
steatosis develops when the rate of fatty acid (FA) input (inﬂux
and synthesis with subsequent esteriﬁcation to TG) is greater than
the rate of FA output (oxidation and outﬂux (very low-density
lipoprotein (VLDL) secretion))29. Previous studies reported that
inhibition of peripheral 5-HT synthesis prevents obesity and
metabolic dysfunction by increasing energy expenditure in BAT
and beige adipocytes in inguinal white adipose tissue
(iWAT)16,17. As such, we thoroughly examined the systemic
metabolic phenotype of HFD-fed Tph1 GKO mice to evaluate
whether increased energy expenditure improved hepatic steatosis
indirectly by reducing FA inﬂux in the liver. Upon HFD, Tph1
GKO mice, in comparison to WT littermates, showed no differ-
ence in body weight (BW) gain, glucose tolerance, insulin sensi-
tivity, plasma lipid proﬁles, and adiposity (Fig. 2a–e, and
Supplementary Fig. 1g). BAT, iWAT, and epididymal white
adipose tissue (eWAT) of Tph1 GKO mice showed no difference
in organ weight and histology compared to WT littermates
(Fig. 2f–k). Especially, no obvious histological changes indicating
BAT activation and beige adipogenesis were observed in BAT and
iWAT of Tph1 GKO mice. In addition, neither Ucp1 expression
in BAT and iWAT nor energy expenditure was different between
Tph1 GKO mice and WT littermates (Fig. 2l–n). These data
indicate that GDS does not affect systemic energy metabolism in
this context. Taken together, systemic energy metabolism does
not seem to play a role in ameliorating HFD-induced hepatic
steatosis in Tph1 GKO mice.
GDS regulates lipogenic pathways in the liver. In order to
identify the relevant metabolic pathways that prevent hepatic
steatosis in Tph1 GKO mice, we performed gene expression
analyses for an extensive array of metabolic markers. The
expression of genes involved in lipogenesis were generally
decreased in the liver of HFD-fed Tph1 GKO mice in comparison
to WT littermates (Fig. 3a). However, the expression of genes
involved in FA uptake, FA oxidation, and VLDL secretion were
not different between HFD-fed Tph1 GKO and WT littermates
(Fig. 3b–d). We next subjected Tph1 GKO and WT littermates to
a methionine–choline-deﬁcient (MCD) diet which induces
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hepatic steatosis by decreasing VLDL secretion rather than
increasing FA input in the liver30. Liver histology, NAS, and
hepatic TG concentrations of Tph1 GKO mice were not different
in comparison to WT littermates fed an MCD diet (Fig. 3e–g). As
inhibition of GDS synthesis does not prevent hepatic steatosis in
Tph1 GKO upon MCD diet, liver FA outﬂux is unlikely to
mediate the GDS effects on liver. Taken together, inhibiting GDS
synthesis ameliorates hepatic steatosis by downregulating lipo-
genic pathways in the liver.
HTR2A mediates the lipogenic action of GDS in the liver. The
physiological action of 5-HT is mediated through numerous 5-
HT receptors (HTRs). To identify the HTR that mediates the role
of GDS in the development of hepatic steatosis, we measured the
expression of HTR genes in the liver (Supplementary Fig. 2a).
Interestingly, among the HTR genes found to be expressed at
detectable levels in the liver, only Htr2a expression was markedly
increased by HFD feeding (Fig. 4a). To determine whether
HTR2A mediates the steatotic effect of GDS in the liver, we
generated mice harboring a ﬂoxed allele of Htr2a and crossed
them with Albumin-Cre mice to generate liver-speciﬁc Htr2a KO
(Albumin-Cre+/–; –Htr2aﬂox/ﬂox, herein named Htr2a LKO) mice
(Supplementary Fig. 2b, c). Htr2a LKO mice showed slightly
reduced liver size and weight compared with WT littermates
(Htr2aﬂox/ﬂox) after 8 weeks of HFD feeding (Fig. 4b, c). Fur-
thermore, HFD-fed Htr2a LKO mice showed decreased hepatic
steatosis as examined by histology, NAS, and hepatic TG con-
centrations (Fig. 4d–f and Supplementary Fig. 2d) without
affecting BW, glucose tolerance, insulin sensitivity, and plasma
lipid proﬁles (Supplementary Fig. 2e–h). Similar to Tph1 GKO
mice, the expression of genes involved in lipogenesis were
decreased whereas genes involved in FA uptake, FA oxidation,
and VLDL secretion were nearly the same in the liver of HFD-fed
Htr2a LKO mice compared to WT littermates (Fig. 4g–j). We also
subject Htr2a LKO mice to an MCD diet for 6 weeks and found
that liver histology, NAS, and hepatic TG levels were not different
with MCD diet-fed WT littermates (Fig. 4k–m). These results
indicate that Htr2a LKO mice are protected against HFD-induced
hepatic steatosis and is a phenocopy of Tph1 GKO mice in terms
of hepatic steatosis.
As HTR2B is the most highly expressed HTR in the liver and
has been associated with hepatic carbohydrate metabolism21, we
generated liver-speciﬁc Htr2b KO (Albumin-Cre+/– ; Htr2bﬂox/
ﬂox, Htr2b LKO) mice and induced hepatic steatosis with 8 weeks
of HFD feeding to examine the role of hepatic HTR2B in steatotic
effects of GDS in the liver. HFD-fed Htr2b LKO mice showed no
difference in liver histology, NAS, and hepatic TG levels
compared with WT littermates (Htr2bﬂox/ﬂox) (Supplementary
Fig. 3a, b, c). From these results, we conﬁrmed that the protective
effect against hepatic steatosis by reducing GDS production was
highly speciﬁc for hepatic HTR2A.
To further explore the molecular pathways underlying the
decreased hepatic lipid accumulation in HFD-fed Htr2a LKO
mice, we performed RNA-seq and proﬁled the liver transcrip-
tomes of HFD-fed Htr2a LKO mice and WT littermates. We
analyzed gene ontology (GO) gene sets by gene set enrichment
analysis (GSEA). Among 5917 GO gene sets, 3614 gene sets with
sufﬁcient number of matched genes were analyzed and 617 gene
sets and 27 gene sets were identiﬁed to be signiﬁcantly enriched in
WT littermates and Htr2a LKO mice, respectively (Supplemen-
tary Data ﬁle). Interestingly, gene sets which contribute to
inﬂammation and ﬁbrosis in nonalcoholic steatohepatitis
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Fig. 1 Gut-derived 5-HT regulates HFD-induced hepatic steatosis. a mRNA expression of genes involved in 5-HT metabolism as assessed by RT-PCR in
liver from 8-week-old C57BL/6J mice. b Plasma 5-HT concentrations of portal blood and peripheral blood in humans. Portal blood concentration set as
100%; n= 9 per group. c–e The 12-week-old male C57BL/6J mice were fed standard chow diet (SCD) or high-fat diet (HFD) for 8 weeks. c Tph1 mRNA
expression in the duodenum, jejunum, ileum, and colon as assessed by qRT-PCR; n= 4 per group. d Duodenal 5-HT levels; n= 3 per group. e Plasma 5-HT
levels in portal blood; n= 3 per group. f–h The 12-week-old WT and Tph1 GKO mice were fed SCD or HFD for 8 weeks. f Representative liver histology by
hematoxylin and eosin (H&E) staining from HFD-fed WT and Tph1 GKO mice. Scale bars, 100 μm. g Nonalcoholic fatty liver disease activity score (NAS) of
HFD-fed WT and Tph1 GKO mice; n= 7–10 per group. h Hepatic triglyceride levels; n= 6–10 per group. Data are expressed as the means ± SEM. *P < 0.5,
**P < 0.01, ***P < 0.001, Student’s t-test (b–e, g) or one-way ANOVA with post hoc Tukey’s test (h)
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pathogenesis as well as gene sets that contribute to steatosis were
signiﬁcantly less enriched in Htr2a LKO mice (Fig. 5a–c)31–40.
Quantitative reverse transcription polymerase chain reaction
(qRT-PCR) analysis further conﬁrmed that proinﬂammatory and
proﬁbrogenic genes were downregulated in the liver of HFD-fed
Htr2a LKO mice (Fig. 5d). These results suggest that inhibiting 5-
HT signaling through hepatic HTR2A can inhibit the progression
of NAFLD.
HTR2A antagonist ameliorates HFD-induced hepatic steatosis.
Taken together with data from Tph1 GKO and Htr2a LKO mice,
we have identiﬁed a previously unknown enterohepatic signaling
pathway for hepatic steatosis mediated by GDS and hepatic
HTR2A. These results led us to evaluate selective HTR2A
antagonism as a novel therapeutic strategy for NAFLD. To this
end, we tested sarpogrelate which is a selective HTR2A antagonist
and mostly used as an antiplatelet agent for the treatment of
peripheral arterial disease41–44. Mice were fed with HFD for
8 weeks and administered sarpogrelate daily using per os for the
same period. As expected, sarpogrelate effectively decreased
hepatic TG accumulation (Fig. 6a–c and Supplementary Fig. 4a).
In addition, closely resembling the effects of genetic deletion of
Htr2a in the liver and Tph1 in the gut, sarpogrelate treatment
resulted in decreased expression of genes involved in lipogenesis
while genes involved in FA uptake, FA oxidation, and VLDL
secretion were not changed in the liver (Fig. 6d–g). We also
examined the systemic metabolic effects of sarpogrelate since
HTR2A is expressed in tissues outside the liver. Mice treated with
sarpogrelate gained less BW upon HFD and their glucose toler-
ance was improved, while insulin tolerance was not affected
(Supplementary Fig. 4b–d). In addition, adipocyte size in iWAT
and crown-like structure in eWAT were decreased in HFD-fed
mice treated with sarpogrelate as compared to vehicle-treated
HFD-fed mice (Supplementary Fig. 4e, f). These results demon-
strate that selective HTR2A antagonist can prevent hepatic stea-
tosis in HFD-fed mice likely through common mechanisms
shared with Tph1 GKO and Htr2a LKO mice.
Discussion
Peripheral 5-HT is emerging as a key regulator of systemic energy
metabolism, modulating various physiological roles in multiple
metabolic tissues16–19,21. Although 5-HT has been known to act
on hepatocytes and promote lipid accumulation in vitro22, con-
troversy still exists whether 5-HT acts directly on liver and reg-
ulates hepatic lipid metabolism in vivo. Here we demonstrate that
inhibition of GDS synthesis by Tph1 GKO mice ameliorates
hepatic steatosis independent of systemic energy homeostasis and
Htr2a LKO mice revealed a phenocopy of Tph1 GKO mice. These
results led us to propose GDS as a direct regulator of hepatic lipid
metabolism via a gut–liver endocrine axis.
In the present study, we have tested the effects of inhibiting
GDS synthesis in two different hepatic steatosis models: HFD
which increases fatty acid inﬂux in the liver and MCD diet which
reduces fatty acid outﬂux in the liver. Both Tph1 GKO and Htr2a
LKO mice were effective only in HFD-induced liver steatosis
without altering systemic energy homeostasis which suggest that
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blocking enterohepatic signaling pathways mediated by GDS and
HTR2A represses TG accumulation in the liver. It is necessary to
further identify detailed molecular mechanisms on how GDS
regulates hepatic lipid disposal in the liver and how inhibition of
HTR2A signaling reduces hepatic TG accumulation.
Our ﬁndings also highlight the functional importance of hepatic
HTR2A signaling in the progression of NAFLD. Inactivation of
HTR2A signaling in the liver using Htr2a LKO attenuated hepatic
steatosis independent of systemic energy homeostasis. Moreover, a
selective HTR2A antagonist showed efﬁcacy in improving hepatic
steatosis as predicted by Tph1 GKO mice and Htr2a LKO mice
phenotypes in HFD-induced hepatic steatosis. Thus, hepatic
HTR2A is a potential target for therapies aiming to prevent the
progression of NAFLD with minimal systemic metabolic effects.
In addition, as the mortality increases geometrically with the
increasing levels of ﬁbrosis in NAFLD patients and many of genes
involved in proinﬂammatory and proﬁbrogenic pathways are
downregulated in Htr2a LKO mice, it would be of interest to test
whether HTR2A antagonism can effectively stop the progression
of hepatic steatosis to ﬁbrosis in the future45. A possible concern
regarding the use of HTR2A antagonist for anti-NAFLD treat-
ment is its potential adverse effects on hepatic regeneration after
acute liver injury20. However, as sarpogrelate shows rare hepato-
toxicity in real world practice, this concern might not be a pro-
blem to use it as an anti-NAFLD drug.
Crane et al.16 reported that HFD-fed Tph1–/– mice indirectly
improved NAFLD through UCP1-dependent thermogenic
mechanisms. Oh et al.17 demonstrated that, similar to Tph1–/–
mice, inhibition of 5-HT production in adipocytes had an anti-
obesity effect by inducing thermogenesis in BAT and iWAT. In
the present study, we demonstrated that HFD-fed Tph1 GKO
mice are protected against hepatic steatosis without affecting
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Fig. 3 Gut-derived 5-HT regulates lipogenic pathways in the liver. a–d The 12-week-old WT and Tph1 GKO mice were fed SCD or HFD for 8 weeks. Relative
mRNA expression of genes involved in lipogenesis (a), FA uptake (b), FA oxidation (c), and VLDL secretion (d) as assessed by qRT-PCR in liver; n= 5 per
group. e–g The 8-week-old WT and Tph1 GKO mice were fed MCD diet for 6 weeks. e Representative liver histology by H&E staining. Scale bars, 100 μm. f
NAS; n= 3–4 per group. g Hepatic triglyceride levels; n= 3–4 per group. Data are expressed as the means ± SEM. **P < 0.01, ***P < 0.001, Student’s t-test
(f, g) or one-way ANOVA with post hoc Tukey’s test (a–d)
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systemic energy homeostasis. Taken together, our current model
dictates that the metabolic phenotype of Tph1–/– mice is the sum
of the phenotype of Tph1 GKO mice and adipocyte-speciﬁc Tph1
KO mice. These ﬁndings suggest that there may be more various
functions of 5-HT in different tissues. Thus, a more detailed study
of the different roles of 5-HT using tissue-speciﬁc KO strategy
will broaden our understanding of the function of this ancient
neurotransmitter.
Methods
Reagents. D-Glucose, nonyl phenoxypolyethoxylethanol (NP-40), and sarpogrelate
hydrochloride were purchased from Sigma-Aldrich (St Louis, MO, USA). TRIzol
reagent was obtained from Invitrogen (Carlsbad, CA, USA).
Animals and diets. The Htr2a-targeted embryonic stem cell clone was obtained
from the European Conditional Mouse Mutagenesis Program (EUCOMM)46. The
mutant Htr2a allele (Htr2atm1a(EUCOMM)Hmgu, Mouse Genome Informatics
(MGI)47 ID: 4946779, Supplementary Fig. 2b) contains L1L2_Bact_P cassette
located between exons 2 and 3 of the Htr2a gene, which is composed of a ﬂippase
recognition target (FRT) site followed by lacZ sequence and loxP site which is
followed by human beta-actin promoter-driven neomycin resistance gene, SV40
polyA, a second FRT site, and second loxP site. A third loxP site is inserted
downstream of exon 3 of the Htr2a gene. Targeted embryonic stem cells were
injected into the blastocysts of BALB/c mice. C57BL/6N × BALB/c chimeric
founders carrying the Htr2atm1a(EUCOMM)Hmgu allele were crossed with C57BL/6J
mice. The germ line transmissions of the F1 mice were analyzed and the conﬁrmed
offspring were crossed with transgenic ﬂippase mice to remove the ﬂanking FRT
sites, resulting in Htr2a-ﬂoxed mice. Htr2a-ﬂoxed mice were backcrossed and
maintained on a C57BL/6J genetic background. Primers for genotyping were as
follows: forward primer 5′-TCTCAGACGTGGAAGGGTCT-3′ and reverse primer
5′-ACTGGTCACTGCTCAAAGGG-3′, which produce products of 252 base pairs
(wild-type allele) or 320 bp (Htr2a-ﬂoxed allele). To generate gut-speciﬁc Tph1
knockout (Tph1 GKO) mice, Tph1ﬂox/ﬂox (MGI: 3837399) mice were crossed with
Villin-Cre (MGI: 2448639) mice. To generate liver-speciﬁc Htr2a knockout (Htr2a
LKO) and liver-speciﬁc Htr2b knockout (Htr2b LKO) mice, Albumin-Cre (MGI:
2176228) mice were crossed with Htr2aﬂox/ﬂox mice and Htr2bﬂox/ﬂox (MGI:
3837400) mice. C57BL/6J mice were purchased from the Charles River Japan
(Yokohama, Japan). Mice were housed in climate-controlled, speciﬁc pathogen-free
barrier facilities under a 12 h light–dark cycle, and chow and water were provided
ad libitum. Mice were fed SCD (Research Diet (New Brunswick, NJ, USA)
D10001), HFD (Research Diet D12492, 60% fat calories), or MCD (Research Diet
A02082002BR) diet. All animal experiments were complied with relevant ethical
regulations. Experimental protocols for this study were approved by the institu-
tional animal care and use committee at the Korea Advanced Institute of Science
and Technology.
Metabolic analysis. To measure the metabolic rate, the mice were individually
housed in an eight-chamber, open-circuit Oxymax/Comprehensive Lab Animal
Monitoring System (Columbus Instruments, Columbus, OH, USA). After 1 day of
acclimation, each mouse was assessed for oxygen consumption, carbon dioxide
a b c d e f
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Fig. 4 HTR2A mediates the lipogenic action of GDS in the liver. a Relative mRNA expression of indicated HTRs as assessed by qRT-PCR in liver of SCD- and
HFD-fed C57BL/6J mice; n= 4 per group. b–j The 12-week-old WT and Htr2a LKO mice were fed SCD or HFD for 8 weeks. Representative gross liver
image (b) and liver weight (c) of HFD-fed WT and Htr2a LKO mice; n= 6–10 per group. Scale bar, 1 cm (b). d Representative liver histology by H&E
staining from HFD-fed WT and Htr2a LKO mice. Scale bars, 100 μm. e NAS of HFD-fed WT and Htr2a LKO mice; n= 6–10 per group. f Hepatic triglyceride
levels; n= 6–10 per group. g–j Relative mRNA expression of genes involved in lipogenesis (g), FA uptake (h), FA oxidation (i), and VLDL secretion (j) as
assessed by qRT-PCR in liver; n= 5 per group. k–m The 8-week-old WT and Htr2a LKO mice were fed MCD diet for 6 weeks. k Representative liver
histology by H&E staining. Scale bars, 100 μm. l NAS; n= 6–8 per group.m Hepatic triglyceride levels; n= 6–8 per group. Data are expressed as the means
± SEM. *P < 0.5, **P < 0.01, ***P < 0.001, Student’s t-test (a, c, e, l, m) or one-way ANOVA with post hoc Tukey’s test (f–j)
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production, activity, and food intake for 72 h with access to diet and water ad
libitum. Heat production was calculated as (3.815+ 1.232 × RER) × VO2, where
RER (respiratory exchange ratio) was calculated as VCO2 VO2–1. Fat mass and lean
body mass were measured using a Minispec time-domain nuclear magnetic reso-
nance analyzer (Bruker Optics, Billerica, MA, USA).
Glucose tolerance test and insulin tolerance test. For the glucose tolerance test,
2 g kg−1 D-glucose in phosphate-buffered saline (PBS) was intraperitoneally
injected into overnight-fasted mice. For the insulin tolerance test, 0.75 U kg−1 or 1
U kg−1 human insulin (Humulin R; Lilly, Indianapolis, IN, USA) was intraper-
itoneally injected into mice after fasting for 6 h. Blood samples were then obtained
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Fig. 6 HTR2A antagonist ameliorates HFD-induced hepatic steatosis. a–g The 12-week-old mice were fed SCD or HFD for 8 weeks and were treated with
vehicle or sarpogrelate daily per os. a Representative liver histology by H&E staining from HFD-fed vehicle and sarpogrelate treated mice. Scale bars, 100
μm. b NAS of HFD-fed vehicle and sarpogrelate-treated mice; n= 6 per group. c Hepatic triglyceride levels; n= 5–6 per group. d–g Relative mRNA
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from the tail vein at 0, 15, 30, 45, 60, 90, and 120 min after injection. Glucose
concentrations were measured using a Gluco DR Plus glucometer (Allmedicus,
Anyang, Korea).
Blood chemistry analysis. Blood samples were collected by retro-orbital bleeding
into plasma separation tubes with lithium heparin (BD Biosciences, Franklin Lakes,
NJ, USA), followed by centrifugation at 1500 × g for 12 min at 4 °C. Enzymatic
colorimetric assay kits for total cholesterol (Roche, Basel, Switzerland), high-
density lipoprotein cholesterol (Roche), triglyceride (Roche), and free fatty acid
(Wako, Osaka, Japan) were used to determine plasma levels on a Cobas 8000
modular analyzer (Roche) at GreenCross LabCell.
Quantiﬁcation of mouse serotonin. To measure mouse platelet poor plasma
(PPP) serotonin, blood samples were collected by retro-orbital bleeding or sam-
pling from the portal vein. To acquire a PPP, we centrifuged twice to ensure no
platelet contamination of supernatant; initially at 700 × g for 10 min and then
1792 × g for further 10 min. Quantiﬁcation of serotonin was performed using an
enzyme-linked immunosorbent assay kit (IBL International, Hamburg, Germany)
according to the manufacturer’s instructions. To measure the levels of serotonin in
the mouse gut, duodenum tissues were washed in PBS, followed by homogeniza-
tion in RIPA buffer (Thermo Fisher Scientiﬁc, Waltham, MA, USA) using a
FastPrep-24 (MP Biomedicals, Santa Ana, CA, USA). The homogenized tissues
were centrifuged at 12,000 × g for 5 min at 4 °C. The supernatants were stored at
−80 °C until analyses. Serotonin levels in tissue lysates were determined with an
enzyme-linked immunosorbent assay kit (IBL International) or liquid
chromatography-mass spectrometry method. Tissue serotonin levels were nor-
malized to protein concentrations using a BCA Protein Assay Kit (Thermo Fisher
Scientiﬁc) of homogenates.
Quantiﬁcation of hepatic triglyceride. Liver tissues were homogenized in 5% NP-
40 using FastPrep-24. To solubilize fat, the homogenates were heated to 95 °C for 5
min and cooled at 23 °C, and repeated. Triglyceride Reagent (Sigma-Aldrich) or PBS
was added and incubated at 37 °C for 30min to hydrolyze TG into glycerol. For the
colorimetric assay of hydrolyzed TG levels, samples were incubated with Free
Glycerol Reagent (Sigma-Aldrich) at 37 °C for 5 min. Differences in absorbance at
540 nm between hydrolyzed or non-hydrolyzed TG were quantiﬁed using a glycerol
standard (Sigma-Aldrich). TG contents were normalized by the protein con-
centrations of homogenates, which were measured with a BCA Protein Assay Kit.
Quantitative RT-PCR analysis. Total RNA extractions from harvested tissues were
performed using TRIzol according to the manufacturer’s protocol. After TURBO
DNase (Invitrogen) treatment, 2 μg of total RNA was used to generate com-
plementary DNA with Superscript III reverse transcriptase (Invitrogen). Quantitative
RT-PCR was performed with Fast SYBR Green Master Mix (Applied Biosystems,
Foster City, CA, USA) and a Viia 7 Real-time PCR System (Applied Biosystems)
according to the manufacturer’s instructions. Gene expression was relatively quanti-
ﬁed based on the delta delta Ct (threshold cycle) method with the beta-actin gene as a
reference gene. The sequences of primers are given in Supplementary Table 1.
Histological analysis. Mouse liver, inguinal white adipose tissue, epididymal white
adipose tissue, and interscapular brown adipose tissue were harvested and ﬁxed in
10% neutral buffered formalin solution (Sigma-Aldrich) and embedded in parafﬁn.
The 5 μm-thick tissues sections were deparafﬁnized, rehydrated, and stained with
hematoxylin and eosin (H&E). For quantitative evaluation of hepatic steatosis,
NAS, which consists of steatosis, lobular inﬂammation, and ballooning, was used.
NAS was determined by a single certiﬁed pathologist, blinded for other
information.
Quantiﬁcation of human blood serotonin. All experiments using human parti-
cipant blood samples were complied with relevant ethical regulations. After pre-
vious approval by the institutional review board of Severance Hospital (4-2015-
0184), and written, informed consent by all subjects, 9 living donors for liver
transplantation were included in this study. Clinical data are given in Supple-
mentary table 2. Body weight and height were measured using a digital scale, and
body mass index was calculated by dividing weight (kg) by the square of height
(m2). Laboratory parameters including complete blood count and differential
count, calcium, phosphorus, glucose, blood urea nitrogen, creatinine (Cr), uric acid,
cholesterol, total protein, albumin, alkaline phosphatase, aspartate transferase,
ALT, total bilirubin, gamma-GTP, TG, high-density lipoprotein (HDL) cholesterol,
low-density lipoprotein (LDL) cholesterol, sodium, potassium, chloride, pro-
thrombin time, and activated prothrombin time were measured within 4 weeks
before living donor hepatectomy. Transient elastography was performed using the
liver Fibroscan (Echosens, Paris, France). Donor hepatectomy was performed
according to standardized procedures. Blood samples for serotonin measurements
were drawn simultaneously from the portal vein and peripheral veins during
operation. Human PPP serotonin levels were measured using ClinRep high-
performance liquid chromatography kit (Recipe, Munich, Germany) at GreenCross
LabCell (Yongin, Korea).
RNA-sequencing. Total RNA was isolated using a RNeasy Plus Mini kit (QIA-
GEN) according to the manufacturer’s instructions. The integrity of the total RNA
was assessed using an Agilent 2100 Bioanalyzer System (Agilent Technologies) and
an Agilent RNA 6000 Nano Kit (Agilent Technologies). Samples with an RNA
Integrity Number (RIN) value >8 were selected for use. Libraries were constructed
using 1 μg total RNA. The RNA sequencing library was prepared using a TruSeq
RNA Sample Prep kit (Illumina) and sequencing was performed using an Illumina
NextSeq500 to generate 100 bp paired-end reads. FastQC (FastQC v0.11.3) and
cut-adapt (v1.1) were used to ﬁlter out sequencing reads of low quality, and the
retained reads were mapped to mouse genome build mm10 using TopHat (TopHat
v2.0.11) with default parameters. HTseq (v0.9.1) was used to generate raw read
counts. GSEA was performed using the GenePattern tool from the Broad Institute,
with version of 5.2 of the Molecular Signature Database (MSigDB; http://www.
broadinstitute.org/gsea/msigdb/index.jsp). HFD-fed Htr2a LKO mice (n= 3) were
compared with WT littermates (n= 3), and representative signiﬁcantly less enri-
ched gene sets with nominal P value of less than 0.05 are presented.
Statistics. All values are expressed as the mean ± standard error of mean and
analyses were performed using the SPSS Statistics version 23 (SPSS, Inc., Chicago,
IL, USA). Two-tailed Student’s t-test or one-way analysis of variance (ANOVA)
with post hoc Tukey’s test were used to compare groups. P values below 0.05 were
considered statistically signiﬁcant. The levels of signiﬁcance indicated in the graphs
are *P < 0.05, **P < 0.01, and ***P < 0.001.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the ﬁndings of this study are available from the authors on
reasonable request. A Reporting Summary for this Article is available as a Sup-
plementary Information ﬁle. Raw data for the RNA sequencing analyses have been
deposited in the NCBI’s Gene Expression Omnibus (GEO) database (GSE 120662).
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